002422 科伦药业
2024/03 - 三个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入6,219,41710.32%21,453,92919,038,21617,277,40816,464,201
减:营业总成本4,767,8432.42%18,277,36317,223,48416,290,48115,745,366
    其中:营业成本2,746,6247.68%10,205,5359,040,1587,660,1527,532,912
               财务费用16,831-82.43%233,761479,834505,647592,380
               资产减值损失0-100.00%(130,551)(44,113)(50,428)(57,488)
公允价值变动收益2,93999.02%14,6669,8614,828421
投资收益111,83525.29%358,882234,580214,82994,825
    其中:对联营企业和合营企业的投资收益112,558-50.67%352,105228,194127,30386,832
营业利润1,632,44844.77%3,654,1432,195,1421,319,8431,009,962
利润总额1,624,79545.65%3,580,4262,067,9191,177,616955,031
减:所得税费用338,994118.01%933,787363,697309,499163,554
净利润1,285,80133.93%2,646,6391,704,221868,117791,477
减:非控股权益259,61378.28%190,527(1,103)(234,438)(37,909)
股东净利润1,026,18826.00%2,456,1121,705,3241,102,554829,386

市场价值指针
每股收益 (元) *0.67017.54%1.6901.2200.7800.580
每股派息 (元) *----0.8000.6160.4260.319
每股净资产 (元) *13.89925.40%13.00910.8649.7219.383
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见--
回页顶
备注: *未调整数据
#只提供简体内容